Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

Podobne zapisy

• Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)
  od: Bateman, Eric D., i wsp.
  Wydane: (2015)
• Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study
  od: D’Urzo, Anthony D, i wsp.
  Wydane: (2014)
• Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
  od: D’Urzo, Anthony D., i wsp.
  Wydane: (2019)
• Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
  od: Moitra, Subhabrata, i wsp.
  Wydane: (2015)
• Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
  od: Singh, Dave, i wsp.
  Wydane: (2017)